COVID-19 has put supply chain risk management practices under the microscope. Coming on the heels of many other, more localized supply issues in the last decade, it has brought about a near-global assessment that supply chains need to be more tightly controlled and redundant – and less dependent on external, at-risk suppliers. In a sense,[…]
LGM Helps Pharma Manage Supply Chain Risks with Added Services Through Nexgen Acquisition
blog, Bulk Active Ingredient, Drug Research & Development API, LGM Pharma, Supply Chain Tags: analytical methods developmentCDMODrug Developmentdrug manufacturingformulations developmentLGM PharmaNexgenpackagingsemi-solidsolid dosesupply chain Nov 02, 2020
Can the U.S. Stop Buying Drugs from China?
blog, Supply Chain Tags: ChinaCOVID-19risk managementsupply chain Oct 04, 2020
The SARS-CoV-2 pandemic has drawn significant attention to just how much US pharmaceutical manufacturers rely on manufacturers outside the United States, both for drug substances and finished dosage drugs. It also has demonstrated the risks associated with global supply chains that are overly reliant on specific regions such as China and India, which may be[…]
A Look at Reshoring Drug Manufacturing: A Q&A With LGM Pharma’s Hamilton Lenox
blog, Supply Chain Tags: ChinaCOVID-19reshoringsupply chain Jun 08, 2020
When SARS-CoV-2 arrived on American shores this Spring, concerns about overextended drug supply chains already were circulating. The issues at hand weren’t new, by any stretch. Environmental, quality and political actions all had impacted drug imports in the last half-dozen years, causing drug shortages and C-suite anxiety. The global pandemic – and the resultant (albeit[…]
Risk Management Practices to Address Pharmaceutical Sourcing Challenges
LGM Pharma, Supply Chain Tags: Drug Developmentpharmaceutical sourcingsupply chain May 03, 2020
It may seem odd to be discussing sourcing challenges considering the overwhelming evidence we now have of what can happen to global (and even local) supply chains when disaster strikes, but while the coronavirus pandemic certainly has put the spotlight on the risks of global supply chains, it by no means created those risks. Indeed,[…]
Confronting Drug Supply Chain Risks
blog, LGM Pharma, Supply Chain Tags: cold chaincorona virusDSCSAserializationsupply chain Mar 02, 2020
The current coronavirus epidemic and subsequent shutdown of travel to and from affected areas in China make supply chain risk management a particularly timely topic this month. While the last thirty years have seen us grow increasingly comfortable with extended, global supply chains, these past few years’ (and months’) events have wreaked havoc on the[…]
How to Select the Right Pharmaceutical Sourcing Model
LGM Pharma Tags: APIspharmaceutical sourcingsourcingstrategic sourcingsupply chain Feb 07, 2020
Farewell to the Blockbuster? The blockbuster drug era is widely reported to be coming to an end. Last year GEN reported (as did many others): “The blockbuster drug model once reigned supreme. Now it is being succeeded by the precision medicine model. During this transition, the pharmaceutical industry may worry about losing the blockbuster model’s[…]
Top 2020 Pharma Supply Chain Logistics Trends
LGM Pharma Tags: 2020 trendsbloglogisticssupply chain Dec 28, 2019
In previous posts, (here and here) we’ve discussed the growing scrutiny on bio/pharmaceutical supply chains. Company executives are increasingly worried about how long their supply chains are – and the risks each layer poses. Regulators are paying close attention and expanding their scope to encompass elements up and down the manufacturing chain – from API[…]
9 Key Sourcing Challenges for Small Pharma
Drug Research & Development API, LGM Pharma Tags: APIAPIsDMFDrug Developmentlogisticspharmascale-upsourcingsupply chainvirtual pharma Sep 05, 2019
Pharma and biopharmaceutical supply chains continue to grow more complex & global. The process of sourcing active pharmaceutical ingredients (APIs) and intermediates has also become more challenging. In 2018, ISR Reports looked at how experience and capacity impact small molecule API outsourcing. Among the findings, about 25% of respondents indicated their company lacked the capacity[…]
